Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring

Carcinoma, Non-Small-Cell Lung Clinical Trial

— CEPAC-TDM  

Official title:

An Open-Label, Randomized, Parallel Group Study of Patients Treated With Paclitaxel With Standard Dosing Versus Pharmacokinetic Guided Dose Adjustment in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01326767
• Other study ID #: C-III-002
• Secondary ID: 2010-023688-16
• Status: Completed
• Phase: Phase 3
• First received: March 29, 2011
• Last updated: January 26, 2016
• Start date: March 2011
• Est. completion date: December 2014

Study information

• Verified date: January 2016
• Source: Central European Society for Anticancer Drug Research
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

This study will be performed on grade IIIb and grade IV Non Small Cell Lung Cancer (NSCLC) chemotherapy naive patients with good performance status. In course of this study, patients will be treated with Paclitaxel in combination with either Cisplatin or Carboplatin in a maximum of six therapy cycles. The goal of this study is to determine, if a pharmakokinetic driven dose adaptation of paclitaxel leads to a reduction of of grade 4 neutropenia, compared to conventional Paclitaxel dosing, without affecting progression free survival and overall survival.

This study includes a biomarker analysis and an optional genetic substudy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 366
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Capable of understanding the protocol requirements and risks, and providing written informed consent.

• Patients with histologically confirmed NSCLC (stage IIIB-IV).

• Patients considered for first-line palliative chemotherapy with paclitaxel in combination with either cisplatin or carboplatin. Patients having received prior adjuvant non taxane-containing adjuvant chemotherapy are eligible.

• At least one bidimensionally measurable lesion according to RECIST 1.1.

• ECOG Performance Status (ECOG-PS) status = 2.

• Female or male patients of 18 to 75 years of age at randomization

• Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum pregnancy test within 1 week prior to beginning treatment on this trial. Nursing patients are excluded. Sexually active men must also use acceptable contraceptive methods (condom).

• An absolute neutrophil count >1,500 cells/ mm3 (= 1.5 G/l).

• Platelet count > 100,000/mm3.

• Total bilirubin = 2 x upper limit of normal.

• AST and ALT = 2.5 x upper limit of normal, or = 5 x upper limit of normal in case of liver metastases.

• Creatinine clearance (according to the Cockcroft-Gault formula) =30ml/min. For patients planned to receive Cisplatin: Creatinine clearance =60ml/min.

• Patients suffering from asymptomatic brain metastases can be enrolled in case corticosteroid therapy is not indicated. Prior irradiation must be completed at least 4 weeks prior to first cycle of treatment.

Exclusion Criteria:

• Serious concomitant systemic disorders (e.g., active infection, severe heart disease, uncontrolled hypertension or diabetes mellitus) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study.

• A history of hypersensitivity reactions to drugs formulated in polyoxyethylated castor oil.

• Having received prior treatment with paclitaxel or cisplatin or carboplatin (other drugs/drug combinations are allowed).

• Concomitant treatment with any targeted drug (licensed or experimental) like bevacizumab or cetuximab.

• Any condition / concomitant disease not allowing chemotherapy with paclitaxel, the platinum compound (carboplatin or cisplatin) or required premedication for the treatment regimen.

• Pregnant/nursing women.

• Individuals known to be seropositive for human immunodeficiency virus, hepatitis C virus, hepatitis B surface antigen or syphilis.

• Treatment with cytotoxic or biologic agents or any experimental drug within the 4 weeks prior to beginning treatment on this study.

• Secondary malignancy within the last five years, with the exception of adequately treated carcinoma-in-situ of the uterine cervix, basal-cell carcinoma of the skin and pTa or pTis urothelial cancer.

• Medical or psychological conditions that would not permit the patient to complete the study or sign informed consent.

• Preexisting neuropathy > grade I NCI-CTC.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• Paclitaxel dosing according to SmPC
Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
• Individualized pharmacokinetically driven paclitaxel dosing
Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration

Locations

Country	Name	City	State
Germany	CESAR Study Center	Bochum
Germany	CESAR study center	Bonn
Germany	CESAR Study Center	Essen
Germany	CESAR study center	Gerlingen
Germany	CESAR study center	Großhansdorf
Germany	CESAR Study Center	Halle an der Saale
Germany	CESAR Study Center	Leer
Germany	CESAR Study Center	Löwenstein
Germany	CESAR Study Center	Munich
Germany	CESAR Study Center	Tübingen
Switzerland	Kantonsspital St. Gallen	St. Gallen

Sponsors (7)

Lead Sponsor	Collaborator
Central European Society for Anticancer Drug Research	Assign Data Management and Biostatistics GmbH, Cantonal Hospital of St. Gallen, Saladax Biomedical, Inc., University Hospital, Basel, Switzerland, University Hospital, Essen, Wake Forest University

Countries where clinical trial is conducted

Germany,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Grad 4 Neutropenia	The rate of grade 4 Neutropenia during the second treatment cycle between the conventional Paclitaxel dosing arm and pharmacokinetically driven Paclitaxel dosing arm is compared. At the same time progression free survival and overall survival must not be affected.	up to 6 weeks on treatment	Yes
Secondary	Objective tumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST v1.1)		24 months	No
Secondary	Progression free survival		24 month	No
Secondary	Overall survival		24 month	No
Secondary	Overall neutropenia	Overall neutropenia ( i.e. during total chemotherapy duration) assessed from clinical hematology data and by model-based estimations of individual neutrophil curves	24 month	Yes
Secondary	Hematological / non-hematological toxicites	Hematological (leucocytopenia, anemia, thrombocytopenia) and non-hematological toxicities (e.g. neurological, musculosceletal and gastrointestinal adverse events)	24 months	Yes
Secondary	Cumulative dose and dose intensity of paclitaxel and platinum drug		24 months	No
Secondary	Incidence of changes from cisplatin to carboplatin and reasons thereof		24 months	No
Secondary	Overall rate of febrile neutropenia and hospitalization due to chemotherapy-associated adverse events		24 months	Yes
Secondary	Health economic analysis using QoL Questionnaires		24 months	No

External Links

•   CESAR - Homepage